161 related articles for article (PubMed ID: 36768934)
1. Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy.
Shibasaki Y; Yokobori T; Sohda M; Shioi I; Ozawa N; Komine C; Suga K; Nakazawa N; Osone K; Shiraishi T; Okada T; Sano A; Sakai M; Ogawa H; Kaira K; Shirabe K; Saeki H
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768934
[TBL] [Abstract][Full Text] [Related]
2. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
Cai Z; Ke J; He X; Yuan R; Chen Y; Wu X; Wang L; Wang J; Lan P; Wu X
Ann Surg Oncol; 2014 Jan; 21(1):179-88. PubMed ID: 23907312
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.
Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
Oncology; 2022; 100(11):576-582. PubMed ID: 36252550
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
6. Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling.
Wang Y; Yang Z; Zhu W; Chen Y; He X; Li J; Han Z; Yang Y; Liu W; Zhang K
Drug Dev Res; 2023 Aug; 84(5):988-998. PubMed ID: 37132439
[TBL] [Abstract][Full Text] [Related]
7. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Kotaka M; Iwamoto S; Satake H; Sakai D; Kudo T; Fukunaga M; Konishi K; Ide Y; Ikumoto T; Tsuji A; Sano Y; Kato T; Sugimoto N; Satoh T; Kanazawa A; Kurata T; Yamanaka T; Tomita N
Int J Clin Oncol; 2020 Aug; 25(8):1515-1522. PubMed ID: 32409917
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
[TBL] [Abstract][Full Text] [Related]
10. Poor Prognosis in Patients With Stage III Colorectal Cancer Receiving Adjuvant FOLFOX/CAPOX Therapy Is Predicted by the Presence of Many Poorly Differentiated Clusters.
Yoshimatsu K; Kono T; Satake M; Ito Y; Shiozawa S; Tanaka H; Higashida M; Okada T; Endo S; Fujiwara Y; Ueno T
Anticancer Res; 2023 Jul; 43(7):3235-3240. PubMed ID: 37352004
[TBL] [Abstract][Full Text] [Related]
11. High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
Nakazawa N; Sohda M; Ide M; Shimoda Y; Ubukata Y; Kuriyama K; Hara K; Sano A; Sakai M; Yokobori T; Ogawa H; Oyama T; Shirabe K; Saeki H
Oncology; 2021; 99(11):732-739. PubMed ID: 34392246
[TBL] [Abstract][Full Text] [Related]
12. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Oriuchi N; Kanai Y; Endo M; Kondo H; Nakajima T; Yamamoto N
Anticancer Res; 2011 Nov; 31(11):3775-82. PubMed ID: 22110199
[TBL] [Abstract][Full Text] [Related]
13. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
[TBL] [Abstract][Full Text] [Related]
14. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
[TBL] [Abstract][Full Text] [Related]
15. Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway.
Li N; Zhang Z; Jiang G; Sun H; Yu D
Front Biosci (Landmark Ed); 2019 Jan; 24(2):303-312. PubMed ID: 30468657
[TBL] [Abstract][Full Text] [Related]
16. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.
Lu M; Zessin AS; Glover W; Hsu DS
PLoS One; 2017; 12(1):e0169439. PubMed ID: 28060954
[TBL] [Abstract][Full Text] [Related]
17. Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer.
Ogawa H; Kaira K; Motegi Y; Yokobori T; Takada T; Katoh R; Osone K; Takahashi R; Katayama C; Oyama T; Kanai Y; Yao T; Asao T; Kuwano H; Shirabe K
Anticancer Res; 2019 May; 39(5):2535-2543. PubMed ID: 31092450
[TBL] [Abstract][Full Text] [Related]
18. Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
Nozawa H; Kawai K; Sasaki K; Murono K; Emoto S; Yokoyama Y; Abe S; Kishikawa J; Nagai Y; Sonoda H; Anzai H; Ozawa T; Ishihara S
Int J Clin Pract; 2021 Nov; 75(11):e14863. PubMed ID: 34516723
[TBL] [Abstract][Full Text] [Related]
19. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
Soveri LM; Lamminmäki A; Hänninen UA; Karhunen M; Bono P; Osterlund P
Acta Oncol; 2019 Apr; 58(4):398-406. PubMed ID: 30638100
[TBL] [Abstract][Full Text] [Related]
20. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
